Drug Trial Radar · NCT06745531
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Jan 6, 2025
Primary completion
Oct 13, 2025
Study completion Oct 20, 2025
Sponsor
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
Conditions
- Hyperphosphatemia Patients on Hemodialysis
Interventions
TS-172 20~60 mg/dayDrug
oral administration of TS-172 20\~60 mg/day
PlaceboDrug
oral administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement rate of the target serum phosphorus levelTime frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.